|1.||Cortes, Javier: 10 articles (12/2015 - 04/2010)|
|2.||Twelves, Chris: 9 articles (12/2015 - 04/2010)|
|3.||Littlefield, Bruce A: 9 articles (10/2013 - 07/2008)|
|4.||Vahdat, Linda T: 8 articles (07/2014 - 06/2009)|
|5.||Awada, Ahmad: 7 articles (12/2015 - 09/2010)|
|6.||Wanders, Jantien: 7 articles (04/2014 - 04/2010)|
|7.||O'Shaughnessy, Joyce: 6 articles (01/2015 - 06/2009)|
|8.||Towle, Murray J: 6 articles (05/2012 - 01/2011)|
|9.||Kaufman, Peter A: 5 articles (12/2015 - 04/2010)|
|10.||Reyderman, Larisa: 5 articles (11/2015 - 02/2012)|
|1.||Breast Neoplasms (Breast Cancer)
12/01/2014 - "In Phase III EMBRACE study, eribulin obtained a statistically significant improvement in the overall survival of pretreated metastatic breast cancer patients. "
03/12/2011 - "Eribulin showed a significant and clinically meaningful improvement in overall survival compared with TPC in women with heavily pretreated metastatic breast cancer. "
10/01/2013 - "Studies of eribulin have shown that the drug is effective in the treatment of previously treated metastatic breast cancer, and has an acceptable toxicity profile. "
01/01/2011 - "Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer."
01/01/2014 - "Oncology nursing support for safe and effective use of eribulin in metastatic breast cancer."
01/01/2014 - "The subgroup analysis showed that a significant improvement in term of partial response and clinical benefit was achieved when eribulin was administered in HER-2 negative tumors (p=0.01 and p=0.004, respectively) and when it is given as third-line (p=0.09 and p=0.02, respectively). "
04/01/2015 - "Furthermore, the efficacy of eribulin was investigated in different tumor subtypes. "
08/01/2013 - "This study assessed the potential of eribulin to affect cardiac repolarization in patients with advanced solid tumors. "
10/01/2012 - "The study determined the recommended dose, MTD, DLTs, safety, pharmacokinetics, and antitumor activity of eribulin administered on Days 1 and 8 of a 21-day cycle in Japanese patients with advanced solid tumors. "
02/01/2012 - "This mass balance study investigated the metabolism and excretion of eribulin, a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, in patients with advanced solid tumors. "
|3.||Neoplasm Metastasis (Metastasis)
11/01/2013 - "Eribulin was effective against the liver metastases for more than 1 year. "
11/01/2013 - "Eribulin was effective against the lung metastases for more than 1 year. "
01/01/2013 - "However, further clinical studies are warranted to determine the clinical effect of eribulin in brain metastases."
01/01/2015 - "Eribulin was active also in brain metastases, with 47% CB. "
10/01/2014 - "Because abnormal tumor microenvironments enhance both drug resistance and metastasis, the apparent ability of eribulin to reverse these aggressive characteristics may contribute to its clinical benefits. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/01/2012 - "Non-small cell lung cancer patients had improved response rates when treated with eribulin in open-label, nonrandomized, Phase II trials reported in abstract form. "
01/01/2012 - "This open-label phase II study assessed the efficacy and tolerability of eribulin, a non-taxane microtubule dynamics inhibitor with novel mechanism of action, as monotherapy in patients who have advanced non-small-cell lung cancer (NSCLC). "
01/01/2012 - "A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer."
07/01/2012 - "In non-small cell lung cancer, median overall survival in eribulin-treated patients has been reported as 9.4 months in an unselected population and varies according to taxane sensitivity: 12.6 months in taxane-sensitive disease versus 8.9 months in taxane-resistant disease. "
07/01/2012 - "Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer."
|5.||Sarcoma (Soft Tissue Sarcoma)
07/01/2015 - "Eribulin Shows Promise in Advanced Sarcoma."
10/01/2011 - "We assessed the activity and safety of eribulin in four strata of patients with different types of soft-tissue sarcoma. "
10/01/2011 - "Eribulin in soft-tissue sarcomas."
10/01/2011 - "Eribulin deserves further study in this setting, based on progression-free survival at 12 weeks in leiomyosarcoma and adipocytic sarcoma. "
10/01/2011 - "Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes."
|8.||ixabepilone (BMS 247550)
|9.||130-nm albumin-bound paclitaxel
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)